Levosimendan Bioglan

Levosimendan, the active ingredient in Levosimendan Bioglan, is a calcium sensitizer presented as an intravenous solution for intravenous administration. It is indicated for the treatment of acute decompensated heart failure, improving cardiac output in adult patients with severe ventricular dysfunction.

GNH USA supplies Levosimendan Bioglan as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres and specialty clinics worldwide under regulated quality standards. The company ensures batch‑to‑batch consistency, proper documentation, and compliance with EU marketing authorisation requirements.

Levosimendan is a calcium sensitizer used in the management of heart failure.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of low cardiac output in hospitalized patients. Chronic heart failure (off‑label): may be considered to enhance hemodynamics when conventional therapy is insufficient. Cardiogenic shock (off‑label): can provide inotropic support while avoiding increased intracellular calcium.

Levosimendan may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Hypotension: reduction in blood pressure, especially after rapid infusion. - Headache: mild to moderate intensity during treatment. - Nausea: occasional gastrointestinal discomfort. - Tachycardia: increased heart rate observed in some patients. - Dizziness: feeling of light‑headedness, often related to blood pressure changes.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis in rare cases. - Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan requires careful monitoring and specific safety measures before and during therapy.

Monitor blood pressure: watch for significant drops, especially during loading dose. Monitor cardiac rhythm: observe for arrhythmias via continuous ECG. Use cautiously in renal impairment: dose adjustment may be needed. Avoid in severe hypotension: contraindicated if systolic pressure is <90 mmHg. Discontinue if allergic reaction occurs: stop infusion and provide appropriate treatment. Store below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Levosimendan can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations. - Other calcium sensitizers: additive inotropic effect leading to arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt desired inotropic response. - Diuretics: enhance volume depletion and hypotension risk. - ACE inhibitors/ARBs: synergistic blood pressure lowering. - Other inotropes (e.g., dobutamine): may require dose adjustments. - Anticoagulants: monitor for bleeding if hypotension occurs.